The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global AL Amyloidosis Therapeutics Market Research Report 2024
Synopsis
The most common kind of systemic amyloidosis is the amyloid light chain (AL) amyloidosis, sometimes referred to as primary amyloidosis. Systemic light-chain (AL) amyloidosis was once thought to be an unstoppable deadly condition.
Global AL Amyloidosis Therapeutics market is projected to reach US$ 3433.8 million in 2029, increasing from US$ 2104 million in 2022, with the CAGR of 7.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole AL Amyloidosis Therapeutics market research.
The AL amyloidosis therapeutics market is driven by the increasing awareness of the disease and advances in medical research. AL amyloidosis is a rare and life-threatening condition caused by the deposition of abnormal proteins in tissues and organs. The rise in diagnostic capabilities and the growing understanding of the disease's pathophysiology have led to the development of targeted therapies, driving market growth. Moreover, the emergence of novel treatment options, such as monoclonal antibodies and proteasome inhibitors, has significantly improved patient outcomes. However, the market also faces challenges, including the rarity of the disease, making clinical trials and drug development more challenging. Additionally, the need for early and accurate diagnosis and the high cost of specialized therapies pose obstacles for both patients and healthcare systems. To succeed, companies must invest in research and development, collaborate with healthcare providers to improve disease awareness and diagnosis, and work towards making AL amyloidosis therapeutics more accessible and affordable for patients in need.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global AL Amyloidosis Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Janssen Pharmaceutical
Prothena
Alexion Pharmaceuticals
Oncopeptides AB
Bristol-Myers Squibb
GlaxoSmithKline Pharmaceuticals Ltd
Eidos Therapeutics, Inc.
Corino Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Pfizer
Segment by Type
Chemotherapy
Supportive Care
Surgery
Stem Cell Transplant
Targeted Therapy
Segment by Application
Hospitals
Clinics
Ambulatory Service Centres
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The AL Amyloidosis Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
The most common kind of systemic amyloidosis is the amyloid light chain (AL) amyloidosis, sometimes referred to as primary amyloidosis. Systemic light-chain (AL) amyloidosis was once thought to be an unstoppable deadly condition.
Global AL Amyloidosis Therapeutics market is projected to reach US$ 3433.8 million in 2029, increasing from US$ 2104 million in 2022, with the CAGR of 7.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole AL Amyloidosis Therapeutics market research.
The AL amyloidosis therapeutics market is driven by the increasing awareness of the disease and advances in medical research. AL amyloidosis is a rare and life-threatening condition caused by the deposition of abnormal proteins in tissues and organs. The rise in diagnostic capabilities and the growing understanding of the disease's pathophysiology have led to the development of targeted therapies, driving market growth. Moreover, the emergence of novel treatment options, such as monoclonal antibodies and proteasome inhibitors, has significantly improved patient outcomes. However, the market also faces challenges, including the rarity of the disease, making clinical trials and drug development more challenging. Additionally, the need for early and accurate diagnosis and the high cost of specialized therapies pose obstacles for both patients and healthcare systems. To succeed, companies must invest in research and development, collaborate with healthcare providers to improve disease awareness and diagnosis, and work towards making AL amyloidosis therapeutics more accessible and affordable for patients in need.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global AL Amyloidosis Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Janssen Pharmaceutical
Prothena
Alexion Pharmaceuticals
Oncopeptides AB
Bristol-Myers Squibb
GlaxoSmithKline Pharmaceuticals Ltd
Eidos Therapeutics, Inc.
Corino Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Pfizer
Segment by Type
Chemotherapy
Supportive Care
Surgery
Stem Cell Transplant
Targeted Therapy
Segment by Application
Hospitals
Clinics
Ambulatory Service Centres
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The AL Amyloidosis Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global AL Amyloidosis Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Supportive Care
1.2.4 Surgery
1.2.5 Stem Cell Transplant
1.2.6 Targeted Therapy
1.3 Market by Application
1.3.1 Global AL Amyloidosis Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Service Centres
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global AL Amyloidosis Therapeutics Market Perspective (2018-2029)
2.2 AL Amyloidosis Therapeutics Growth Trends by Region
2.2.1 Global AL Amyloidosis Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 AL Amyloidosis Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 AL Amyloidosis Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 AL Amyloidosis Therapeutics Market Dynamics
2.3.1 AL Amyloidosis Therapeutics Industry Trends
2.3.2 AL Amyloidosis Therapeutics Market Drivers
2.3.3 AL Amyloidosis Therapeutics Market Challenges
2.3.4 AL Amyloidosis Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top AL Amyloidosis Therapeutics Players by Revenue
3.1.1 Global Top AL Amyloidosis Therapeutics Players by Revenue (2018-2023)
3.1.2 Global AL Amyloidosis Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global AL Amyloidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by AL Amyloidosis Therapeutics Revenue
3.4 Global AL Amyloidosis Therapeutics Market Concentration Ratio
3.4.1 Global AL Amyloidosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by AL Amyloidosis Therapeutics Revenue in 2022
3.5 AL Amyloidosis Therapeutics Key Players Head office and Area Served
3.6 Key Players AL Amyloidosis Therapeutics Product Solution and Service
3.7 Date of Enter into AL Amyloidosis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 AL Amyloidosis Therapeutics Breakdown Data by Type
4.1 Global AL Amyloidosis Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global AL Amyloidosis Therapeutics Forecasted Market Size by Type (2024-2029)
5 AL Amyloidosis Therapeutics Breakdown Data by Application
5.1 Global AL Amyloidosis Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global AL Amyloidosis Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America AL Amyloidosis Therapeutics Market Size (2018-2029)
6.2 North America AL Amyloidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America AL Amyloidosis Therapeutics Market Size by Country (2018-2023)
6.4 North America AL Amyloidosis Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe AL Amyloidosis Therapeutics Market Size (2018-2029)
7.2 Europe AL Amyloidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe AL Amyloidosis Therapeutics Market Size by Country (2018-2023)
7.4 Europe AL Amyloidosis Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific AL Amyloidosis Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific AL Amyloidosis Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific AL Amyloidosis Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific AL Amyloidosis Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America AL Amyloidosis Therapeutics Market Size (2018-2029)
9.2 Latin America AL Amyloidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America AL Amyloidosis Therapeutics Market Size by Country (2018-2023)
9.4 Latin America AL Amyloidosis Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa AL Amyloidosis Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa AL Amyloidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa AL Amyloidosis Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa AL Amyloidosis Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Janssen Pharmaceutical
11.1.1 Janssen Pharmaceutical Company Detail
11.1.2 Janssen Pharmaceutical Business Overview
11.1.3 Janssen Pharmaceutical AL Amyloidosis Therapeutics Introduction
11.1.4 Janssen Pharmaceutical Revenue in AL Amyloidosis Therapeutics Business (2018-2023)
11.1.5 Janssen Pharmaceutical Recent Development
11.2 Prothena
11.2.1 Prothena Company Detail
11.2.2 Prothena Business Overview
11.2.3 Prothena AL Amyloidosis Therapeutics Introduction
11.2.4 Prothena Revenue in AL Amyloidosis Therapeutics Business (2018-2023)
11.2.5 Prothena Recent Development
11.3 Alexion Pharmaceuticals
11.3.1 Alexion Pharmaceuticals Company Detail
11.3.2 Alexion Pharmaceuticals Business Overview
11.3.3 Alexion Pharmaceuticals AL Amyloidosis Therapeutics Introduction
11.3.4 Alexion Pharmaceuticals Revenue in AL Amyloidosis Therapeutics Business (2018-2023)
11.3.5 Alexion Pharmaceuticals Recent Development
11.4 Oncopeptides AB
11.4.1 Oncopeptides AB Company Detail
11.4.2 Oncopeptides AB Business Overview
11.4.3 Oncopeptides AB AL Amyloidosis Therapeutics Introduction
11.4.4 Oncopeptides AB Revenue in AL Amyloidosis Therapeutics Business (2018-2023)
11.4.5 Oncopeptides AB Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Detail
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb AL Amyloidosis Therapeutics Introduction
11.5.4 Bristol-Myers Squibb Revenue in AL Amyloidosis Therapeutics Business (2018-2023)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 GlaxoSmithKline Pharmaceuticals Ltd
11.6.1 GlaxoSmithKline Pharmaceuticals Ltd Company Detail
11.6.2 GlaxoSmithKline Pharmaceuticals Ltd Business Overview
11.6.3 GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Introduction
11.6.4 GlaxoSmithKline Pharmaceuticals Ltd Revenue in AL Amyloidosis Therapeutics Business (2018-2023)
11.6.5 GlaxoSmithKline Pharmaceuticals Ltd Recent Development
11.7 Eidos Therapeutics, Inc.
11.7.1 Eidos Therapeutics, Inc. Company Detail
11.7.2 Eidos Therapeutics, Inc. Business Overview
11.7.3 Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Introduction
11.7.4 Eidos Therapeutics, Inc. Revenue in AL Amyloidosis Therapeutics Business (2018-2023)
11.7.5 Eidos Therapeutics, Inc. Recent Development
11.8 Corino Therapeutics, Inc.
11.8.1 Corino Therapeutics, Inc. Company Detail
11.8.2 Corino Therapeutics, Inc. Business Overview
11.8.3 Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Introduction
11.8.4 Corino Therapeutics, Inc. Revenue in AL Amyloidosis Therapeutics Business (2018-2023)
11.8.5 Corino Therapeutics, Inc. Recent Development
11.9 Spectrum Pharmaceuticals, Inc.
11.9.1 Spectrum Pharmaceuticals, Inc. Company Detail
11.9.2 Spectrum Pharmaceuticals, Inc. Business Overview
11.9.3 Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Introduction
11.9.4 Spectrum Pharmaceuticals, Inc. Revenue in AL Amyloidosis Therapeutics Business (2018-2023)
11.9.5 Spectrum Pharmaceuticals, Inc. Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Detail
11.10.2 Pfizer Business Overview
11.10.3 Pfizer AL Amyloidosis Therapeutics Introduction
11.10.4 Pfizer Revenue in AL Amyloidosis Therapeutics Business (2018-2023)
11.10.5 Pfizer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
